As this drug is an upgraded version of prostate cancer treatment, which is increasing every year, many patients are expected to benefit if health insurance benefits are applied. On the 16th, the HIRA foretold the reimbursement standards for anticancer drugs, which include the establishment of new reimbursements for ADT and combination therapy for Erleada's hormone-responsive metastatic prostate cancer (mHSPC) patients. The effective date is the 1st of the following month.

According to the announced reimbursement criteria, Erleada is covered as first-line therapy, block therapy (ADT), and combination therapy for mHSPC patients. ADT is an androgen deprivation therapy, limited to orchiectomy, LHRH agonist